Author:
Sager Petra,Kaiser Astrid,Schumann Sara,Ludescher Beate,Brysch Wolfgang
Reference3 articles.
1. Efficacy of MP1032 in hospitalised patients with COVID-19;Liu;Lancet Reg Health Eur,2024
2. Efficacy and safety of MP1032 plus standard-of-care compared to standard-of-care in hospitalised patients with COVID-19: a multicentre, randomised double-blind, placebo-controlled phase 2a trial;Sager;Lancet Reg Health Eur,2023
3. Immune-modulating drug MP1032 with SARS-CoV-2 activity in vitro: a potential multi-target approach for prevention and early intervention treatment of COVID-19;Schumann;Int J Mol Sci,2020